



Europäisches
Patentamt

European
Patent Office

Office européen
des brevets

EP00/5202

REC'D 25 JUL 2000

WIPO

PCT

4

Bescheinigung

Certificate

Attestation

Die angehefteten Unterla-
gen stimmen mit der
ursprünglich eingereichten
Fassung der auf dem näch-
sten Blatt bezeichneten
europäischen Patentanmel-
dung überein.

The attached documents
are exact copies of the
European patent application
described on the following
page, as originally filed.

Les documents fixés à
cette attestation sont
conformes à la version
initialement déposée de
la demande de brevet
européen spécifiée à la
page suivante.

Patentanmeldung Nr. Patent application No. Demande de brevet n°

99401385.2

PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

Der Präsident des Europäischen Patentamts;
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets
p.o.

I.L.C. HATTEN-HECKMAN

DEN HAAG, DEN
THE HAGUE,
LA HAYE, LE

18/07/00

This Page Blank (uspto)



Europäisches
Patentamt

European
Patent Office

Office européen
des brevets

Blatt 2 der Bescheinigung
Sheet 2 of the certificate
Page 2 de l'attestation

Anmeldung Nr.:
Application no.: 99401385.2
Demande n°:

Anmeldetag:
Date of filing: 09/06/99
Date de dépôt:

Anmelder:
Applicant(s):
Demandeur(s):
I.D.M. IMMUNO-DESIGNED MOLECULES
75011 Paris
FRANCE

Bezeichnung der Erfindung:
Title of the invention:
Titre de l'invention:

Molecular complexes presenting high affinity binding with respect to monocyte derived cells and their use in therapy

In Anspruch genommene Priorität(en) / Priority(ies) claimed / Priorité(s) revendiquée(s)

Staat:
State:
Pays:

Tag:
Date:
Date:

Aktenzeichen:
File no.
Numéro de dépôt:

Internationale Patentklassifikation:
International Patent classification:
Classification internationale des brevets:

A61K35/12, A61K35/74, A61K35/76, A61K35/14, A61K39/00, C12N5/06, C12N5/08, A61P35/00, A61P31/00, A61P43/00

Am Anmeldetag benannte Vertragsstaaten:
Contracting states designated at date of filing: AT/BE/CH/CY/DE/DK/ES/FI/FR/GB/GR/IE/IT/LI/LU/MC/NL/PT/SE
Etats contractants désignés lors du dépôt:

Bemerkungen:
Remarks:
Remarques:

See for title page 1 of the description

This Page Blank (uspto)

**NEW MOLECULAR COMPLEXES PRESENTING HIGH AFFINITY
BINDING WITH RESPECT TO MONOCYTE DERIVED CELLS AND
THEIR USES IN THERAPY**

5

The invention relates to new molecular complexes presenting high affinity binding with respect to monocyte derived cells and their uses in therapy.

Blood monocytes in physiological conditions leave the blood stream flow to reach tissues where they differentiate into resident macrophages (for example:
10 lung macrophages, kupffer cells in liver, skin macrophages, osteoclasts in bone, microglial cells in brain ...), or into professional antigen presenting cells (for example : dendritic cells in peripheral tissues or lymphnodes, Langerhans cells in skin ...).

Differentiation of blood monocytes can also be achieved *ex vivo* under
15 defined culture conditions (see applications WO94/26875, WO96/22781, WO97/44441, WO99/13054); however, the macrophages or the dendritic cells obtained in culture do not achieve tissue specificity similar to the one obtained *in vivo*).

Furthermore, the induction of an immune response has been documented
20 when the antigens are known. However, regarding the induction of an immune response towards unknown antigens (particularly tumor antigens), a targeting of these antigens to specific receptors of the antigen presenting cells is required ; this is an objective of the present invention.

One of the aims of the invention is to provide monocyte derived cells
25 which have acquired a tissue specificity.

Another aim of the invention is to provide an *ex vivo* method for stimulating cellular and/or humoral immune responses against unknown components of a tumor tissue extract.

Another aim of the invention is to provide *in vivo* specific cellular and/or
30 humoral immune responses against unknown component of tumor tissue extract.

All these aims are achieved through the invention, which gives access to new molecular complexes having high affinity with tissue extracts on the one hand, and high affinity with monocyte derived cells on the other hand.

More precisely, the invention relates to a molecular complex between a
5 tissue extract containing at least one known component and unknown components and a molecular vector comprising a particle bearing polypeptides and/or sugars, said molecular vector being able to recognize :

- said known component of said tissue extract, and
 - a phagocytic receptor of monocyte derived cells,
- 10 with the proviso that polypeptides are different from antibodies.

The expression "*known component*" means identified tissue antigens, polypeptides or oligosaccharides or an hapten expressed or transfected on the cell membrane of tissues or tumors.

The expression "*unknown component*" means "complex mixture of
15 proteins and saccharides present in cellular extracts of tumors or tissues (lysates, apoptotic extracts,...)

The expression "*molecular vector*" corresponds to a carrier of molecular structure.

The expression "*recognize said known component of said tissue extract*"
20 means that it presents a high affinity and/or avidity ($>10^{-6}$ M) for said component.

The expression "*recognize a phagocytic receptor of monocyte derived cells*" means that it is a ligand for such receptor.

The expression "*polypeptides are different from antibodies*" means that
25 they are not monoclonal or polyclonal antibodies with Fc and Fab parts.

A phagocytic receptor of monocyte derived cells is a receptor such that, when interacting with a ligand, in this case, the molecular complex, it initiates uptake of said ligand.

The phagocytic status means that the monocyte derived cells have gained,
30 after a few days of culture, for instance, about 4 to about 10 days, a high

phagocytic activity. (This phagocytic activity can be visualized and quantified by measuring, for instance under the microscope, the uptake of yeast particles).

The expression "*monocyte derived cells (or MDCs)*" designates macrophages or dendritic cells derived from blood monocytes.

5 According to an advantageous embodiment, the invention relates to a molecular complex wherein the molecular vector comprises a particle bearing polypeptides and/or sugars such that :

- at least one of the said polypeptides and/or sugars recognizes said known surface component of the tissue extract,
- 10 - at least one of the said sugars and/or polypeptides recognizes phagocytic receptors of monocyte derived cells such as receptors for mannose or for oligosaccharides or Fc receptors of monocyte derived cells.

There are thus four different possibilities :

1) at least one of the said polypeptides of the particle can recognize a
15 known component of the tissue extract and at least one of the said polypeptides of the particle can recognize a phagocytic receptor of monocyte derived cells,

2) at least one of the said polypeptides of the particle can recognize a known component of the tissue extract and at least one of the said sugars of the particle can recognize a phagocytic receptor of monocyte derived cells,

20 3) at least one of the said sugars can recognize a known component of the tissue extract and at least one of the said sugars of the particle can recognize a phagocytic receptor of monocyte derived cells,

4) at least one of the said sugars can recognize a known component of the tissue extract and at least one of the said polypeptides of the particle can
25 recognize a phagocytic receptor of monocyte derived cells.

The nature of the bond between the sugar and the known component is formed of hydrogen, Vanderwaals, hydrophobic interactions and salt bridges.

The nature of the bond between the sugar and the monocyte derived cells is mainly hydrogen, Vanderwaals, hydrophobic interactions and salt bridges.

The nature of the bond between the polypeptides and the known component is mainly hydrogen, Vanderwaals, hydrophobic interactions and salt bridges.

5 The nature of the bond between the polypeptide and monocyte derived cells is mainly hydrogen, Vanderwaals, hydrophobic interactions and salt bridges.

In an advantageous embodiment of the molecular complex of the invention, the molecular vector comprises or is a particle of about 0,1 to about 2 μm of biocompatible polymer comprising :

- 10 - surface polypeptides and/or sugars, preferably covalently linked to the surface of said particle, with said surface polypeptides and/or sugars recognizing said known component of the tissue extract, and
- mannosylated residues recognizing the mannose or oligosaccharide receptors of monocyte derived cells.

15 According to an advantageous embodiment, in the molecular complex of the invention, the tissue extract comprises macroscopic fragments or killed or irradiated or haptenised human or animal tumor cells such as lysates or apoptotic bodies, or killed pathogens, such as viruses or bacteria.

20 According to an advantageous embodiment, in the molecular complex of the invention, the polypeptide of the particle recognises one known epitope of the tissue extract chosen among known tumor antigens such as (tumor peptide antigen) MelanA/MART-1, MAGE, BAGE, GAGE families, MUC, EGF-R, ERB-2, PSA, PSMA, HSP70, CEA, P53, RAS, Tyrosinase, gp100,....

25 According to another advantageous embodiment, in the molecular complex of the invention, the tissue extract comprises normal tissue parts such as tissue membranes, tissue factors, tissue proteins, macroscopic fragments of tissue such as lysates or apoptotic bodies, said tissue being originating from any part of human or animal body or cellular extracts thereof, in particular from thymus, lung, pancreas, cartilage, endothelium, neuromuscular junctions,

prostate, sexual organs, bladder, muscles, peripheral nerves, CNS extracts, spleen, liver, bone, heart, skin cells.

5 In the molecular complex of the invention, the polypeptide and/or sugars of said particle form(s) high affinity binding with any component of said tissue extract.

In the molecular complex of the invention, the polypeptide and/or sugars of the particle form(s) high affinity binding with a phagocytic receptor of a monocyte derived cell.

10 The expression "*high affinity binding*" means that the affinity constant K_a is equal to or higher than 10^6 M or the equilibrium dissociation constant K_d is equal to or lower than 10^{-6} M.

According to an advantageous embodiment, the monocyte derived cells recognized by the molecular complex of the invention are macrophages, dendritic cells, or antigen presenting cells.

15 The invention also relates to monocyte derived cells such as prepared according to a process comprising the step of contacting monocyte derived cells with a molecular complex according to the invention.

20 The invention also relates to monocyte derived cells such as prepared according to a process comprising contacting monocyte derived cells with a molecular complex according to the invention, under conditions enabling phagocytosis of said molecular complex by said monocyte derived cells, intracellular degradation and processing of the known and unknown components of the tumor tissue extract and the presentation of said known and unknown components on the peripheral membrane of the monocyte derived cells together
25 with MHC I and MHC II molecules.

The monocyte derived cells are immature dendritic cells for the phagocytosis, which then mature for the induction of immune response.

The invention also relates to monocyte derived cells such as prepared according to a process comprising contacting monocyte derived cells with a

molecular complex as described above, under conditions enabling phagocytosis of such molecular complex by the monocyte derived cells.

The monocyte derived cells are non-activated macrophages (4/8 days of culture).

- 5 The invention also relates to an *ex vivo* method for stimulating cellular and/or humoral immune responses against unknown components of a tumor tissue extract comprising contacting monocyte derived cells with a molecular complex according to the invention, under conditions enabling phagocytosis of said molecular complex by monocyte derived cells, intracellular degradation and
- 10 processing of the known and of unknown components of the tumor tissue extract and the presentation of said known and unknown components on the peripheral membrane of the monocyte derived cells, together with MHC I and II molecules.

- The invention also relates to a method of inducing *in vivo* specific
- 15 cellular and/or humoral immune responses against unknown components of tumor tissue extract comprising injections of a molecular complex according to the invention, for instance by intramuscular, subcutaneous, local or intravenous route.

- According to an advantageous embodiment, said method of inducing *in*
- 20 *vivo* specific cellular and/or humoral responses against unknown components of a tumor tissue extract, comprises sequential and/or simultaneous injections of monocyte derived cells presenting known and unknown components of said tumor tissue extract, together with MHC I and II molecules, as defined above, and of molecular complexes as described above.

- 25 The invention also relates to a method for conditioning *ex vivo* monocytes derived cells, and preferentially macrophages, for them to acquire tissue specificity, comprising contacting monocyte derived cells with a molecular complex according to the invention, under conditions enabling phagocytosis of said molecular complex by the monocyte derived cells.

The expression "*conditioning ex vivo human monocyte derived cells*" means that after phagocytosis of specific tissue extracts, the MDCs acquire characteristics of the corresponding tissue macrophages.

The expression "*acquire tissue specificity*" means that when the MDCs
5 are injected *in vivo*, they will (concentrate) accumulate preferentially in the corresponding tissue.

The invention also relates to a method of treatment of diseases involving accumulation of conditioned monocyte derived cells as described above in specific tissue to induce tissue repair and/or regeneration comprising :

10 - either simultaneous and/or sequential injections of monocyte derived cells and of a molecular complex according to the invention, under conditions enabling phagocytosis,

- or injection of the monocyte derived cells which have previously phagocytosed a molecular complex according to the invention.

15 The expression "*accumulation of conditioned monocyte derived cells*" in a tissue means that, after systemic injection, at least 10% of the cells injected accumulate in the tissue within 24 h.

In the invention, the monocyte derived cells which are advantageously involved are human monocyte derived cells.

20 By way of example, the diseases which can be treated by the method of the invention are tissue/organ destruction or degenerative diseases, when tissue repair is required (skin, bone, nerve, neuromuscular regeneration).

The invention also relates to pharmaceutical compositions comprising, as active substance, monocyte derived cells which have been contacted with a
25 molecular complex according to the invention, under conditions enabling phagocytosis of said molecular complex by monocyte derived cells, intracellular degradation and processing of the known and of unknown components of the tumor tissue extract and the presentation of said known and unknown components on the peripheral membrane of the monocyte derived cells, together
30 with MHC I and II molecules.

The invention also relates to pharmaceutical compositions comprising, as active substance, monocyte derived cells, and preferentially macrophages, which have been contacted with a molecular complex according to the invention, under conditions enabling phagocytosis of said molecular complex by the monocyte
5 derived cells.

EXAMPLE 1 : Application to a human melanoma tumor:

Apoptotic bodies are generated from a human melanoma cell line M17 by UV irradiation. They are added in basic medium to microparticles of 0.2 to 2
10 μm with covalently linked annexin V polypeptides and mannosyl residues. Annexin V presents a high affinity for phosphatidyl serine residues expressed on apoptotic bodies.

The microparticles contain a magnetic core and the molecular complexes (tumor apoptotic bodies - microparticles) are isolated on magnets. A working
15 bank of molecular melanoma complexes is constituted and kept frozen.

Patients with metastatic melanoma are injected into 4 subcutaneous sites, one intradermal site plus one intravenous site with the defrost preparation.

The injections are repeated after 2 weeks and again one month
20 later. Interaction with dendritic cells is occurring locally in the patient.

The induction of a specific immune response against the melanoma tumor is documented by humoral and cellular T responses against the known MAGE and MelanA/MART antigens expressed by the M17 cell line. The global antitumoral effect is shown by shrinkage ($> 50\%$) of subcutaneous
25 metastases, this response requires immune activation against multiple melanoma tumor antigens or than the targeted antigen.

EXAMPLE 2 : Application to tissue repair in a murine model:

Microparticles of 0.2 to 2 μm size presenting at their surface mannosyl residues are added to a suspension of killed murine hepatocytes, and molecular complexes are formed.

Macrophages are obtained by differentiation of murine bone marrow
5 cells in culture and labelled with indium or an emitter of positons (example: Fluor 18).

These macrophages are grown for 16 h in the presence (a) or the absence (b) of molecular complexes.

Two millions of these macrophages are injected intravenously to
10 the mice. After 2 hours, the biodistribution of the macrophages in the animal tissues is measured by gamma counting or PET-scan (SMV International). In case (a), 90% of the macrophages injected are in the liver while in case (b), only 20% of the macrophages are in liver. This indicates that the macrophages grown in the presence of the molecular complexes have gained a liver tissue specificity.
15 If necrosis of the liver is previously induced, a fast regeneration is seen a few days after macrophage injection.

This Page Blank (uspto)

CLAIMS

1. Molecular complex between a tissue extract containing at least one
5 known component and unknown components and a molecular vector comprising
a particle bearing sugars and/or polypeptides, said molecular vector being able
to recognize :

- said known component of said tissue extract, and
- a phagocytic receptor of monocyte derived cells,

10 with the proviso that said polypeptides are different from antibodies.

2. Molecular complex according to claim 1, wherein the molecular
vector comprises a particle bearing polypeptides and/or sugars such that :

- at least one of the said polypeptides and/or sugars recognizes said known
15 surface component of the tissue extract,
- at least one of the said sugars and/or polypeptides recognizes phagocytic
receptors of monocyte derived cells such as receptors for mannose or for
oligosaccharides or Fc receptors of monocyte derived cells.

20 3. Molecular complex according to claim 2, wherein the molecular
vector comprises or is a particle of about 0,1 to about 2 μm of biocompatible
polymer comprising

- surface polypeptides and/or sugars, preferably covalently linked to the surface
of said particle, with said surface polypeptides and/or sugars recognizing said
25 known component of the tissue extract, and
- mannolysated residues recognizing the mannose or oligosaccharide receptors of
monocyte derived cells.

4. Molecular complex according to anyone of claims 1 to 3, wherein the
30 tissue extract comprises macroscopic fragments or killed or irradiated or

haptенized human or animal tumor cells such as lysates or apoptotic bodies, or killed pathogens, such as viruses or bacteria.

5 5. Molecular complex according to claim 4, wherein the polypeptide of the particle recognises one known epitope of the tissue extract chosen among known tumor antigens such as (tumor peptide antigen) MelanA/MART-1, MAGE, BAGE, GAGE families ; MUC, EGF-R, ERB-2, PSA, PSMA, HSP70, CEA, P53, RAS, Tyrosinase, gp100,...

10 6. Molecular complex according to anyone of claims 1 to 3, wherein the tissue extract comprises normal tissue parts such as tissue membranes, tissue factors, tissue proteins, macroscopic fragments of tissue such as lysates or apoptotic bodies, said tissue being originating from any part of human or animal body or cellular extracts thereof, in particular from thymus, lung,
15 pancreas, cartilage, endothelium, neuromuscular junctions, prostate, sexual organs, bladder, muscles, peripheral nerves, CNS extracts, spleen, liver, bone, heart, skin cells.

20 7. Molecular complex according to claim 6, wherein the polypeptide and/or sugars of said particle forms high affinity binding with any component of said tissue extract.

25 8. Molecular complex according to anyone of claims 1 to 7, wherein the monocyte derived cells recognized by said molecular complex are macrophages, dendritic cells, or antigen presenting cells.

 9. Monocyte derived cells such as prepared according to a process comprising the step of contacting monocyte derived cells with a molecular complex according to anyone of claims 1 to 8.

10. Monocyte derived cells such as prepared according to a process comprising contacting monocyte derived cells with a molecular complex according to anyone of claims 1 to 5, under conditions enabling phagocytosis of said molecular complex by said monocyte derived cells, intracellular degradation
5 and processing of the known and unknown components of the tumor tissue extract and the presentation of said known and unknown components on the peripheral membrane of the monocyte derived cells together with MHC I and MHC II molecules.

10 11. Monocyte derived cells such as prepared according to a process comprising contacting monocyte derived cells with a molecular complex according to any one of claims 1 to 3, 6 and 7, under conditions enabling phagocytosis of such molecular complex by the monocyte derived cells.

15 12. *Ex vivo* method for stimulating cellular and/or humoral immune responses against unknown components of a tumor tissue extract comprising contacting monocyte derived cells with a molecular complex according to anyone of claims 1 to 5, under conditions enabling phagocytosis of said molecular complex by monocyte derived cells, intracellular degradation and
20 processing of the known and of unknown components of the tumor tissue extract and the presentation of said known and unknown components on the peripheral membrane of the monocyte derived cells, together with MHC I and II molecules.

25 13. Method of inducing *in vivo* specific cellular and/or humoral immune responses against unknown components of tumor tissue extract comprising injections of a molecular complex according to anyone of claims 1 to 5, for instance by intramuscular, subcutaneous, local or intravenous route.

14. Method of inducing *in vivo* specific cellular and/or humoral responses against unknown components of a tumor tissue extract, comprising sequential and/or simultaneous injections of monocyte derived cells presenting known and unknown components of said tumor tissue extract, together with
5 MHC I and II molecules, as defined in claim 12, and of molecular complexes according to anyone of claims 1 to 5.

15. Method for conditioning *ex vivo* human monocytes derived cells, and preferentially macrophages, for them to acquire tissue specificity, comprising
10 contacting monocyte derived cells with a molecular complex according to anyone of claims 1 to 3, or 6 and 7, under conditions enabling phagocytosis of such molecular complex by the monocyte derived cells.

16. Method of treatment of diseases involving accumulation of
15 conditioned monocyte derived cells according to claim 15 in specific tissue to induce tissue repair and/or regeneration comprising :

- either simultaneous and/or sequential injections of monocyte derived cells and of a molecular complex according to anyone of claims 1 to 3, or 6 and 7, under conditions enabling phagocytosis,
- 20 - or injection of the monocyte derived cells which have previously phagocytosed a molecular complex according to anyone of claims 1 to 3 or 6 and 7.

ABSTRACT**NEW MOLECULAR COMPLEXES PRESENTING HIGH AFFINITY
5 BINDING WITH RESPECT TO MONOCYTE DERIVED CELLS AND
THEIR USES IN THERAPY**

The invention concerns a molecular complex between a tissue extract
10 containing at least one known component and unknown components and a
molecular vector comprising a particle bearing sugars and/or polypeptides, said
molecular vector being able to recognize :

- said known component of said tissue extract, and
- a phagocytic receptor of monocyte derived cells,

15 with the proviso that said polypeptides are different from antibodies.

20 (no figure)

This Page Blank (uspto)